ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

HEW Finally Moves On Distribution Of Chemicals

September 7, 1979

“5 A Day” Review Underway to Check Program’s Health at NCI.

March 31, 2000

NCI Awards $15M For Studies Of Glycobiology.

September 28, 2007

Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease

April 25, 2014

Competing Core, P01 Grants Held To 7% Increases To Help Spread $$ Around

December 7, 1979

Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.

January 14, 2005